Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study

Table 2 Total and gender-specific affective disorder (AD)^aincidence density by diabetes mellitus (DM) status.^b

	Total		Men		Women
Descriptor	Cases/total study group, n	ID (95% CI)^c	Cases/total study group, n	ID (95% CI)^c	Cases/total study group, n	ID (95% CI)^c
DM without OAAs	42/5619	74.7 (52.2 to 97.3)	11/2599	42.3 (17.4 to 67.3)	31/3019	102 (66.7 to 138)
Met only	43/5627	76.4 (53.7 to 99.2)	18/2637	68.2 (36.8 to 99.7)	25/2989	83.6 (51.0 to 116)
DM without OAAs	140/14503	96.5 (80.6 to 112)	52/7101	73.2 (53.4 to 93.1)	88/7402	118 (94.2 to 143)
SUs only	145/13370	108 (90.9 to 126)	59/6581	89.6 (66.9 to 112)	86/6788	126 (100 to 153)
DM without OAAs	282/30957	91.1 (80.5 to 101)^d	100/14064	71.1 (57.2 to 85.0)^e	182/16893	107 (92.2 to 123)^f
SUs + Met	127/32236	39.4 (32.6 to 46.2)^d	45/14791	30.4 (21.5 to 39.3)^e	82/17444	47.0 (36.9 to 57.2)^f

^aAD diagnoses include ICD-9-CM (296) and the equivalent Taiwanese A-code (A212).
^aMet, metformin; OAAs: oral anti-diabetic agents; SUs, sulfonylureas.
^cID (95% CI): incidence density per 10,000 person-years (95% confidence interval).
^d-fThe same superscript vertically indicates that there is a significant difference between the two groups.

ISSN: 1741-7015